Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMPN 2026 | Emerging therapeutic strategies and future directions in MPNs

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the emerging landscape of myeloproliferative neoplasms (MPNs), highlighting the potential of targeted therapies, such as anti-calreticulin antibodies and novel JAK inhibitors. Dr Masarova also emphasizes the importance of addressing anemia in patients with MPNs, with agents like luspatercept showing promise, and notes that the field will likely evolve towards exploring treatment-free remissions. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think there is so much happening in myeloproliferative neoplasms these years that we are all grasping with CD advances. I think very, very interesting and very important is the more targeted pathways where we are finally developing and going after the calreticulin mutations or the specific JAK inhibitors that we’ve never been able to use. I think one of the most important spaces to watch would be the calreticulin, where there are currently anti-calreticulin antibodies...

I think there is so much happening in myeloproliferative neoplasms these years that we are all grasping with CD advances. I think very, very interesting and very important is the more targeted pathways where we are finally developing and going after the calreticulin mutations or the specific JAK inhibitors that we’ve never been able to use. I think one of the most important spaces to watch would be the calreticulin, where there are currently anti-calreticulin antibodies. Some already have human data, such as the INCA-909. Some are expected to have new data released this year by the end of the year, like a J&J. And some are entering their space. So targets of calreticulin is, I think, kind of a breakthrough in MPNs because we were never able to go after the disease-initiating clones and show that maybe if we can reverse the target or the disease-modifying event, we could actually block the disease and prevent it from progression or even hopefully cure it. But that’s going to be to learn. So I think that is very important. There we were going to learn how to use these agents, what’s the durability of responses, whether to use them on a single agent setting, whether to use them repeatedly, how to sequence them, what to expect in the long term. So I think that’s a very important part on all calreticulin-mutated MPNs that includes ET and myelofibrosis. Then the novel JAK inhibitors, they’re also entering the space, seem to be more effective, deeper, and selective for either JAK2 or type 2, where they have a better confirmation and how they target the clones. So that’s important to see. They definitely seem to be much more deeper and broader. So let’s see whether they’re going to be durable and tolerable. And there’s new ones that are also coming in the space. It’s important. I think the anemia is also a very important topic because targeting anemia has always been kind of our need for MF patients. And now agents such as luspatercept seem to be very interesting, not only as an anemia agent, but also as an agent that would be helpful to guide and suppress the clones. So I think there’s a lot to talk about. I’m excited that the field is moving forward and going more deeper and targeted. I’m sure we’re going to learn how to best sequence to use these agents, whether we could actually finally lead to some disease-modifying effects to even stop therapies in some patients. But getting more agents in the space, they’re safer, they’re more effective. I think the next question for us will come once we achieve a decrease in the allele burden, are we going to end up in a space of CML of treatment-free remissions? How can we do that? Do we have enough assay? Do we understand what we’re measuring? Where is it going to be sustained? And all of that question will probably shape the field. But I think it’s very important to watch it because we’ll learn a lot in this decade.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.